Answers are grounded in this paper and cite their sources.
Clinical investigation reveals therapeutic response to nivolumab in metastatic sarcomas, suggesting rationale for broader checkpoint inhibitor trials.
These data provide a rationale for further exploring the efficacy of nivolumab and other checkpoint inhibitors in soft tissue and bone sarcoma.
No takes yet. Share an insight, caveat, or question.
Paoluzzi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: